Semaphorin‑4F (SEMA4F) is a protein encoded by the SEMA4F gene in humans. It belongs to the semaphorin family, a large group of secreted or membrane‑bound proteins that serve as guidance cues in neuronal development and also play roles in immune regulation, angiogenesis, and tumor progression.
Gene and Protein Structure
- Gene locus: The SEMA4F gene is located on chromosome 5q33.1 in the human genome.
- Protein size: The canonical isoform of Semaphorin‑4F consists of approximately 861 amino acids. It includes an N‑terminal Sema domain, a PSI (plexin‑semaphorin‑integrin) domain, and a C‑terminal PDZ‑binding motif. The protein is a type I transmembrane protein with a short intracellular tail that can interact with intracellular signaling molecules.
Biological Functions
- Neuronal guidance: As a member of class 4 semaphorins, SEMA4F functions as a ligand for plexin receptors (particularly Plexin‑B family members) to regulate axonal repulsion and attraction during nervous system development.
- Immune modulation: Semaphorin‑4F can influence immune cell behavior, including T‑cell activation and cytokine production, though the precise mechanisms remain under investigation.
- Angiogenesis and vascular biology: Evidence indicates that SEMA4F contributes to endothelial cell migration and tube formation, implicating it in blood vessel formation and remodeling.
- Cell‑cell interaction: The PDZ‑binding motif enables interactions with scaffold proteins such as PSD‑95, linking extracellular cues to intracellular signaling cascades.
Expression Profile
- Tissue distribution: SEMA4F mRNA is expressed in the central nervous system, peripheral nerves, thymus, spleen, and various vascular tissues. Protein expression has been detected in neuronal growth cones, endothelial cells, and certain immune cell subsets.
- Developmental regulation: Expression levels are notably high during embryonic neural development and can be modulated in response to injury or pathological stimuli.
Clinical Significance
- Cancer: Aberrant expression of SEMA4F has been reported in several tumor types, including colorectal, breast, and lung cancers. Over‑expression is sometimes associated with enhanced tumor cell migration and poor prognosis, suggesting a role in metastatic processes.
- Neurological disorders: Altered semaphorin signaling, including that mediated by SEMA4F, has been implicated in neurodevelopmental disorders and neurodegenerative diseases, although direct causal links require further validation.
- Therapeutic potential: Targeting the SEMA4F‑plexin axis is under exploration as a strategy to modulate angiogenesis, immune responses, or tumor progression. No FDA‑approved therapies specifically targeting SEMA4F are currently available.
Interactions
- Receptors: Primarily binds to Plexin‑B1 and Plexin‑B2, initiating intracellular signaling pathways involving Rho GTPases, PI3K/Akt, and MAPK cascades.
- Intracellular partners: Through its PDZ‑binding motif, interacts with scaffold proteins (e.g., PSD‑95, MUPP1) that organize signaling complexes at the plasma membrane.
Research Tools
- Antibodies: Commercially available monoclonal and polyclonal antibodies target the extracellular Sema domain or the intracellular tail for immunohistochemistry, western blot, and flow cytometry.
- Knock‑out models: Mouse Sema4f knockout lines have been generated to study its role in neural circuitry and vascular development.
References
- Primary literature describing the cloning and characterization of human SEMA4F (e.g., published in Journal of Biological Chemistry, 2003).
- Reviews on semaphorin signaling pathways (e.g., Nature Reviews Neuroscience, 2015) that include sections on class 4 semaphorins.
- Clinical studies associating SEMA4F expression with cancer outcomes (e.g., Oncotarget, 2018).
All statements are based on peer‑reviewed scientific literature and publicly available genomic databases.
